<DOC>
	<DOCNO>NCT01483638</DOCNO>
	<brief_summary>The purpose study evaluate maintenance therapy axitinib patient metastatic colorectal carcinoma</brief_summary>
	<brief_title>Axitinib Maintenance Treatment Patients With Metastatic CRC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>1 . Patient must histological cytological confirm colorectal adenocarcinoma metastatic disease document diagnostic imaging study , susceptible radical surgery metastasis , low burden disease . 2 . Patients without progressive disease six month standard first line chemotherapy regimen CRC ( 5FU capecitabine ± oxaliplatin irinotecan ± bevacizumab cetuximab ) . 3 . Patient must least one measurable lesion define modified RECIST criterion . 4 . Male female , age ≥18 year . 5 . ECOG performance status 0 1 life expectancy ≥12 week . 6 . Adequate organ function define follow criterion : absolute neutrophil count ( ANC ) ≥1500 cells/mm3 ; platelet ≥100,000 cells/mm3 . Hemoglobin ≥9.0 g/dL . AST ALT ≤2.5 x upper limit normal ( ULN ) , unless liver metastasis case AST ALT ≤5.0 x ULN ; Total bilirubin ≤1.5 x ULN ; Alkaline phosphatase &lt; 300U/l Serum creatinine ≤1.5 x ULN calculate creatinine clearance ≥50 mL/min ; Urinary protein &lt; 2+ urine dipstick . If dipstick ≥2+ 24hour urine collection do patient may enter urinary protein &lt; 2 g per 24 hour . 7 . At least 4 week since end prior systemic treatment , radiotherapy , surgical procedure resolution treatmentrelated toxicity NCI CTCAE Version 4.0 grade ≤1 back baseline except alopecia neurotoxicity 8 . No evidence pre exist uncontrolled hypertension document 2 baseline blood pressure read take least 1 hour apart . The baseline systolic blood pressure reading must ≤140 mm Hg , baseline diastolic blood pressure reading must ≤90 mm Hg . Patients whose hypertension control antihypertensive therapy eligible . 9 . Women childbearing potential must negative serum urine pregnancy test within 3 day prior treatment . 10 . Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . 11 . Willingness ability comply schedule visit , treatment plan ( include willingness take either AG013736 placebo accord randomization ) , laboratory test , study procedure . 1 . Gastrointestinal abnormality include : inability take oral medication ; requirement intravenous alimentation ; prior surgical procedure affect absorption include total gastric resection ; treatment active peptic ulcer disease past 6 month ; active gastrointestinal bleeding , unrelated cancer , evidence hematemesis , hematochezia melena past 3 month without evidence resolution document endoscopy colonoscopy ; malabsorption syndrome . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior start , unless affected area remove surgically 2 . Current use anticipate need treatment drug know potent CYP3A4 inhibitor ( ie , grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , erythromycin , telithromycin , clarithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir delavirdine ) . 3 . Current use anticipate need treatment drug know CYP3A4 CYP1A2 inducer ( ie , carbamazepine , dexamethasone , felbamate , omeprazole , phenobarbital , phenytoin , amobarbital , nevirapine , primidone , rifabutin , rifampin , St. John 's wort ) . 4 . History haemorrhage within past 6 month , include gross hemoptysis hematuria . 5 . Requirement anticoagulant therapy oral vitamin K antagonists . Lowdose anticoagulant maintenance patency central venous access devise prevention deep venous thrombosis allow . Therapeutic use low molecular weight heparin allow . 6 . Active seizure disorder evidence brain metastasis , spinal cord compression , carcinomatous meningitis . 7 . A serious uncontrolled medical disorder active infection would impair ability receive study treatment . 8 . Any follow within 12 month prior study drug administration : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack 6 month deep vein thrombosis pulmonary embolism . 9 . Ongoing cardiac dysrhythmias NCI CTCAE grade ≥2 , atrial fibrillation grade , QTc interval &gt; 450 msec male &gt; 470 msec female . 10 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness . 11 . History malignancy ( colorectal cancer ) except treat curative intent skin cancer ( melanoma ) , situ breast situ cervical cancer , treat curative intent cancer evidence disease 2 year . 12 . Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol . 13 . Female patient pregnant lactating , men woman reproductive potential willing able employ effective method birth control/contraception prevent pregnancy treatment 6 month discontinue study treatment . The definition effective contraception agreement local regulation base judgment principal investigator designate associate . 14 . Other severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study . 15 . Current , recent ( within 4 week study treatment administration ) , plan participation experimental therapeutic drug study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>duration disease response</keyword>
	<keyword>axitinib</keyword>
</DOC>